SLC5A2 and type 2 diabetes mellitus: While SGLT2 inhibitors often result in a weight loss of approximately 2–3 kg, no reduction in muscle mass or bone mineral density was observed with empagliflozin administration in the EMPA-ELDERLY study [9], which evaluated the effects of empagliflozin on glucose levels and muscle mass in Japanese patients with type 2 diabetes aged 65 years or older with a body mass index (BMI) of 22 kg/m2 or higher.